Co-expression of TNF receptors 1 and 2 on melanomas facilitates soluble TNF-induced resistance to MAPK pathway inhibitors

Co-expression of TNF receptors 1 and 2 on melanomas facilitates soluble TNF-induced resistance to MAPK pathway inhibitors

Abstract Background The effectiveness of MAPK pathway inhibitors (MAPKi) used to treat patients with BRAF-mutant melanoma is limited by a range of resistance mechanisms, including soluble TNF (solTNF)-mediated NF-kB signaling. solTNF preferentially signals through type-1 TNF receptor (TNFR1), howeve...

Full description

Bibliographic Details
Main Authors: Cindy A. Sander, Elizabeth A. Rush, Jian Shi, Lidia M. R. B. Arantes, Raymond J. Tesi, Mark A. Ross, Michael J. Calderon, Simon C. Watkins, John M. Kirkwood, Robert L. Ferris, Lisa H. Butterfield, Lazar Vujanovic
Format: Article
Language:English
Published: BMC 2022-07-01
Series:Journal of Translational Medicine
Subjects:
Melanoma
Soluble TNF
TNF receptor 1
TNF receptor 2
CD271
Drug resistance
Online Access:https://doi.org/10.1186/s12967-022-03538-w

Internet

https://doi.org/10.1186/s12967-022-03538-w

Similar Items